Introduction
Background and rationale
Objective
Study methods
Trial design
Randomization and blinding
Sample size
Data monitoring
Timing of final analysis
Statistical principles
Confidence intervals and P values
Adherence and protocol deviations
Analysis populations
-
Medication compliance is 80–120%;
-
Treatment meets efficacy endpoints as protocol required, and the primary outcomes are measurable;
-
No major violations of the protocol (including inclusion and exclusion criteria).
Trial population
Demographic and baseline characteristics
Analysis
Outcome definitions
-
Mean daytime and nighttime SBP in ABPM, change from baseline
-
24-h, daytime, and nighttime mean diastolic blood pressure (DBP) in ABPM, change from baseline
-
Morning BP surge in ABPM, change from baseline
-
Office blood pressure measurement (OBPM), change from baseline
-
Home blood pressure measurement (HBPM), change from baseline
-
Heart rate, change from baseline
-
Blood pressure control rate
Timepoint | Enrolment and allocation | Treatment phase 1 | Washout phase | Treatment phase 2 | |||
---|---|---|---|---|---|---|---|
0 day | 1–4 weeks | 4th week | 5–6 weeks | 6th week | 7–10 weeks | 10th week | |
HBPM | X | X | X | X | X | X | X |
OBPM | X | X | X | X | |||
Biochemistry results | |||||||
Electrolyte | X | X | X | ||||
FBG | X | X | X | ||||
Renal function | X | X | X | ||||
Liver function | X | X | X | ||||
Urine routine | X | X | X | ||||
Tests | |||||||
ECG | X | X | X | ||||
ABPM | X | X | X | X |
Criteria for blood pressure control
Definition of baseline
Statistical hypothesis
Analysis of primary outcome
Analysis of secondary outcomes
Analysis of safety outcomes
Outcomes | Analysis methods |
---|---|
Primary outcome | |
Changes in 24-h SBP | Linear mixed-effects model |
Secondary outcomes | |
Changes in 24-h DBP | Linear mixed-effects model |
Changes in daytime BP | Linear mixed-effects model |
Changes in nighttime BP | Linear mixed-effects model |
Changes in morning BP surge | Linear mixed-effects model |
Changes in office BP | Linear mixed-effects model |
Changes in home BP | Linear mixed-effects model |
Changes in heart rate | Linear mixed-effects model |
BP control rate | Paired chi-square test |
TTR of home BP | Linear mixed-effects model |
Safety outcomes | |
Adverse event | Chi-square tests or Fisher’s exact probability method |
Changes in biochemistry results | Linear mixed-effects model |
Changes in QT interval | Linear mixed-effects model |
Sensitivity analysis
-
FAS for analysis of primary and secondary outcomes;
-
Different ways of managing missing data for analysis of HBPM;
-
Retention or exclusion of outliers if applicable.
Subgroup analysis
-
Sex (male or female)
-
Age (< 45 years or ≥ 45years, which is used to classify youth and middle age)
-
Diabetes mellitus (with or without)